JD.com Pledges 22 Billion Yuan Housing Support for Couriers as China’s Instant Retail Competition Heats Up 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
S&P 500 Slides as AI Chip Stocks Tumble, Cooling Tech Rally 
SpaceX Edges Toward Landmark IPO as Elon Musk Confirms Plans 
Wall Street Futures Dip as Broadcom Slides, Tech Weighed Down Despite Dovish Fed Signals 
Fed Rate Cut Signals Balance Between Inflation and Jobs, Says Mary Daly 
Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 
GameStop Misses Q3 Revenue Estimates as Digital Shift Pressures Growth 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
Wall Street Futures Slip as Oracle Earnings Miss Reignites AI Spending Concerns 
Apple App Store Injunction Largely Upheld as Appeals Court Rules on Epic Games Case 
Gold Prices Hold Firm as Markets Await Fed Rate Cut; Silver Surges to Record High 
Modi and Trump Hold Phone Call as India Seeks Relief From U.S. Tariffs Over Russian Oil Trade 
US Signals Openness to New Trade Deal as Brazil Shows Willingness, Says USTR Greer 
Asian Stocks Rally as Tech Rebounds, China Lags on Nvidia Competition Concerns 
Celltrion, a South Korean pharmaceutical company, formulated a COVID-19 antibody treatment, and it is reportedly ready to deliver the drug to the United States and Europe. With its new treatment, the company has now made the world’s third drug for coronavirus.
Now it is likely to enter the European and U.S. markets before this year ends, as per The Korea Herald. This information was revealed in a report that was released on Monday, Aug. 23.
Lee Dong Geon, an analyst at Shinhan Investment, said that Celltrion will be applying for the issuance of emergency use authorization for its Regkirona COVID-19 antibody treatment. It is hoped that the US Food and Drug Administration will approve this drug that is also called the CT-P59 for EUA.
Moreover, it was predicted that it would not be long until Celltrion’s Regkirona is approved. In fact, it may be out in the U.S. market as early as the fourth quarter of this year. As for the EU market, it was estimated that it could obtain regulatory approval from the Europen Medicine Agency before October since it is already under review.
Apparently, once Celltrion succeeded in rolling out Regkirona in the U.S. and Europe, the company’s position in the pharmaceutical business will surely improve, and this will be felt and observed in the coming months.
In any case, Rekirona is an antibody treatment for coronavirus, and it is the first drug to be developed by Celltrion. It already received a green light from South Korea, Indonesia, and recently, in Brazil. The pharma firm said that as soon as the EMA gives its approval, it will immediately ship the drug to the EU.
Celltrion said that this treatment could shorten the number of treatment days for patients with COVID-19. What’s more, it could also prevent the condition of patients from getting severe.
Meanwhile, as soon as the news of Celltrion’s possible shipment of Regkirona to major markets in the world, Pulse News reported that the company’s shares soared, gaining 6.77 percent to close at ₩284,000 or around $241.97 on Kospi. It was added that it finished 8.21 percent higher and Celltrion Healthcare also went up by 7.94 percent.
